Purple Biotech (PPBT) CEO details RSUs and major stock options
Rhea-AI Filing Summary
PURPLE BIOTECH LTD. Chief Executive Officer Gil Efron reported his initial ownership, showing direct holdings of 15,750,000 Ordinary Shares. This includes 12,375,000 unvested restricted stock units that vest over time and are settled in Ordinary Shares, which may be represented by American Depositary Shares, each currently equal to 2,000 Ordinary Shares.
He also holds stock options to purchase 1,500,000 Ordinary Shares at $0.095054688 per share expiring on May 23, 2027; 3,750,000 Ordinary Shares at $0.0765625 per share expiring on July 11, 2027; and 13,500,000 Ordinary Shares at $0.00309375 per share expiring on October 21, 2030, with 1,125,000 already vested and the remaining 12,375,000 vesting in equal quarterly installments until October 21, 2028.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Efron Gil
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 18,750,000 shares (Direct);
Ordinary Shares — 15,750,000 shares (Direct)
Footnotes (4)
- F1. Includes 12,375,000 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.
- F2. Represents stock option to purchase 1,500,000 Ordinary Shares (equivalent to 750 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The Ordinary Shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.095054688 per Ordinary Share and the option expires on May 23, 2027.
- F3. Represents stock option to purchase 3,750,000 Ordinary Shares (equivalent to 1,875 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The Ordinary Shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.0765625 per Ordinary Share and the option expires on July 11, 2027.
- F4. Represents stock option to purchase 13,500,000 Ordinary Shares (equivalent to 6,750 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 1,125,000 Ordinary Shares are vested and exercisable, with the remaining options to purchase 12,375,000 Ordinary Shares vesting in equal quarterly installments until October 21, 2028. The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030.
Key Figures
Direct Ordinary Share holdings: 15,750,000 Ordinary Shares
Unvested RSUs: 12,375,000 RSUs
Option grant 1: 1,500,000 shares at $0.095054688
+3 more
6 metrics
Direct Ordinary Share holdings
15,750,000 Ordinary Shares
Total direct holdings reported by CEO Gil Efron
Unvested RSUs
12,375,000 RSUs
Each RSU for one Ordinary Share; time-based vesting
Option grant 1
1,500,000 shares at $0.095054688
Stock option; expires May 23, 2027
Option grant 2
3,750,000 shares at $0.0765625
Stock option; expires July 11, 2027
Option grant 3
13,500,000 shares at $0.00309375
Stock option; 1,125,000 vested; expires October 21, 2030
ADS ratio
1 ADS = 2,000 Ordinary Shares
Current representation of Ordinary Shares by ADSs
Key Terms
restricted stock units ("RSUs"), American Depositary Shares, Equity-Based Incentive Plan, time-based vesting conditions, +1 more
5 terms
restricted stock units ("RSUs") financial
"Includes 12,375,000 unvested restricted stock units ("RSUs"), each with respect to one ordinary share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Equity-Based Incentive Plan financial
"issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan."
time-based vesting conditions financial
"The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares."
unvested restricted stock units financial
"Includes 12,375,000 unvested restricted stock units ("RSUs"), each with respect to one ordinary share"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What initial holdings did PPBT CEO Gil Efron report on his Form 3?
Gil Efron reported direct holdings of 15,750,000 Ordinary Shares of Purple Biotech Ltd. The position includes both currently owned shares and equity awards, giving investors a clear view of his initial economic stake as Chief Executive Officer.
How many RSUs does the PPBT CEO hold and how do they vest?
Gil Efron holds 12,375,000 unvested restricted stock units (RSUs), each for one Ordinary Share. These RSUs are subject to time-based vesting conditions and settle in Ordinary Shares, aligning his compensation with the company’s long-term performance through gradual vesting.
What stock options were disclosed for the PPBT CEO in this filing?
The CEO holds options for 1,500,000 Ordinary Shares at $0.095054688, 3,750,000 at $0.0765625, and 13,500,000 at $0.00309375 per share. These options were issued under the 2016 Equity-Based Incentive Plan and have specified expiration dates.
Are the CEO’s stock options under a specific Purple Biotech equity plan?
Yes. All disclosed options were granted under Purple Biotech’s 2016 Equity-Based Incentive Plan. This plan governs key terms such as vesting, exercisability, and expiration, and is a central component of the CEO’s long-term equity compensation structure.